Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can special heart checkups protect cancer patients from their own treatment?

NCT ID NCT03882580

Knowledge-focused Sponsor: Groupe Hospitalier Pitie-Salpetriere Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Some cancer drugs cause rare but serious heart and metabolic problems. This study follows 5,000 cancer patients across several French hospitals who receive a dedicated heart checkup and ongoing follow-up through cardio-oncology programs. Researchers track how many patients benefit from this monitoring and look for links between specific anticancer drugs and cardiovascular side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anticancer drugs and treatments used in routine oncology care
What this could lead to
If the approach works, it could shape how cancer teams monitor and protect patients' hearts during treatment, catching dangerous side effects earlier.
What could go wrong
This is an observational study in routine care, not a controlled experiment, so it cannot prove that cardio-oncology checkups cause better outcomes. Benefits may reflect who gets referred rather than the checkups themselves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2019

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients suffering (or having suffered) from a cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Suffering a cancer * Evaluated within a cardio-oncology program Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer cancer-related condition Cardiotoxicity cardiovascular disorder Drug-Related Side Effects and Adverse Reactions heart disorder heart failure metabolic disease vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac complication Cardiac disorder Cardiac insufficiency Cardiovascular complication Cardiovascular insufficiency Metabolic disorder Oncologic complications Vascular disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM

    RECRUITING

    Paris, France, 75013, France

  • AP-HP, Saint-Antoine Hospital, Department of cardiology

    RECRUITING

    Paris, 75012, France

  • AP-HP, Tenon Hospital, Department of Cardiology

    RECRUITING

    Paris, 75020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.